

Maria-Luisa Sulis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8191128/publications.pdf>

Version: 2024-02-01

28
papers

1,047
citations

516710

16
h-index

610901

24
g-index

28
all docs

28
docs citations

28
times ranked

2335
citing authors

#	ARTICLE	IF	CITATIONS
1	Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2106-2118.	1.6	45
2	Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28719.	1.5	26
3	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Cancer Discovery</i> , 2021, 11, 1424-1439.	9.4	16
4	Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2020, 1, 1113-1127.	13.2	32
5	Covalent inhibition of NSD1 histone methyltransferase. <i>Nature Chemical Biology</i> , 2020, 16, 1403-1410.	8.0	52
6	Identification of a secondary RET mutation in a pediatric patient with relapsed acute myeloid leukemia leads to the diagnosis and treatment of asymptomatic metastatic medullary thyroid cancer in a parent: a case for sequencing the germline. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003889.	1.2	2
7	Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27062.	1.5	48
8	Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. <i>Nature</i> , 2018, 553, 511-514.	27.8	90
9	Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26952.	1.5	31
10	Reply to comment on: Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27082.	1.5	0
11	Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. <i>Leukemia</i> , 2018, 32, 2316-2325.	7.2	88
12	Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. <i>Blood Advances</i> , 2018, 2, 1449-1458.	5.2	73
13	Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27256.	1.5	26
14	Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia. <i>Blood</i> , 2018, 132, 1405-1405.	1.4	5
15	Matched targeted therapy for pediatric patients with relapsed, refractory or high-risk leukemias: A report from the LEAP consortium.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10518-10518.	1.6	1
16	Multisite external validation of a risk prediction model for the diagnosis of blood stream infections in febrile pediatric oncology patients without severe neutropenia. <i>Cancer</i> , 2017, 123, 3781-3790.	4.1	18
17	Diagnostic yield of bronchoalveolar lavage in immunocompromised children with malignant and non-malignant disorders. <i>Pediatric Pulmonology</i> , 2017, 52, 820-826.	2.0	21
18	Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group. <i>Pediatric Hematology and Oncology</i> , 2017, 34, 355-364.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Precision Medicine in Children and Young Adults with Hematologic Malignancies and Blood Disorders: The Columbia University Experience. <i>Frontiers in Pediatrics</i> , 2017, 5, 265.	1.9	29
20	Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations. <i>Genome Medicine</i> , 2016, 8, 133.	8.2	147
21	Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11306-11311.	7.1	151
22	Randomized Study of Pegaspargase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001. <i>Blood</i> , 2016, 128, 175-175.	1.4	11
23	Excellent Outcome of Children with Down Syndrome (DS) and Acute Lymphoblastic Leukemia (ALL) Treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols 00-001 and 05-001. <i>Blood</i> , 2016, 128, 761-761.	1.4	0
24	Risk assessment in children presenting with fever and chemotherapy-induced neutropenia.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10078-10078.	1.6	0
25	Childhood de novo CD5+ Diffuse Large B-cell Lymphoma: a Separate Entity?. <i>Annals of Clinical and Laboratory Science</i> , 2015, 45, 574-81.	0.2	0
26	NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. <i>Blood</i> , 2008, 112, 733-740.	1.4	116
27	Inhibition of NOTCH1 Signaling Reverses Glucocorticoid Resistance in T-ALL.. <i>Blood</i> , 2007, 110, 151-151.	1.4	4
28	Veno-occlusive disease in pediatric patients receiving actinomycin D and vincristine only for the treatment of rhabdomyosarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 843-6.	0.6	14